Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BRL29060A · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| BRL29060A | DRUG | - |
| paroxetine hydrochloride hydrate | DRUG | - |
Inclusion criteria: * Diagnosis of Social Anxiety Disorder (SAD) (300.23 Social Phobia/Social Anxiety Disorder) according to DSM-IV-TR criteria. * Must give a written informed consent. * If the patient is under 20, both the patient himself/herself and his/her proxy consenter must give written infor...
BRL29060A is an investigational small molecule being studied for the treatment of Social Phobia, a psychiatric condition also known as social anxiety disorder. It is currently in Phase 3 clinical development.
BRL29060A is being developed by GSK plc, a global pharmaceutical company traded on the New York Stock Exchange under the ticker symbol GSK.
BRL29060A is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed.
BRL29060A has one completed Phase 3 clinical trial, identified as NCT00264654, titled 'Long-term Study Of Paroxetine in Women and Men'. The trial enrolled 50 participants with Social Phobia in Japan and was not randomized or double-blinded.
BRL29060A is the drug being studied in a clinical trial titled 'Long-term Study Of Paroxetine in Women and Men'. The trial name suggests that BRL29060A may be paroxetine, but this has not been explicitly confirmed in the available information.